Good morning, Boston. Here are the five most important things you need to know to get your busy day started, and why I can’t be in two places at once tonight.

Slow biotech IPOs? Not for this venture firm

Allison DeAngelis reports on the lack of profits venture-investment firms have seen from the sluggish biotech IPO activity lately — all except for Flagship Pioneering, which has seen exit profits in the hundreds of millions of dollars this year.

GE shareholders reject bid to split CEO, chair…

Boston Biz Journal